JP2011518546A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011518546A5 JP2011518546A5 JP2011502087A JP2011502087A JP2011518546A5 JP 2011518546 A5 JP2011518546 A5 JP 2011518546A5 JP 2011502087 A JP2011502087 A JP 2011502087A JP 2011502087 A JP2011502087 A JP 2011502087A JP 2011518546 A5 JP2011518546 A5 JP 2011518546A5
- Authority
- JP
- Japan
- Prior art keywords
- vegf
- pdgfr
- bispecific antibody
- residues
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 16
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 16
- 102000004965 antibodies Human genes 0.000 claims 16
- 108090001123 antibodies Proteins 0.000 claims 16
- 102100004939 PDGFRB Human genes 0.000 claims 12
- 101710018346 PDGFRB Proteins 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000038129 antigens Human genes 0.000 claims 6
- 108091007172 antigens Proteins 0.000 claims 6
- 229920000023 polynucleotide Polymers 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 230000002491 angiogenic Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000009745 Eye Disease Diseases 0.000 claims 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 2
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000005017 Glioblastoma Diseases 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 206010065630 Iris neovascularisation Diseases 0.000 claims 1
- 208000002780 Macular Degeneration Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Claims (18)
- PDGFRβ及びVEGF−Aの両方を中和する二重特異性抗体であって、該二重特異性抗体は、
(i)PDGFRβの細胞外ドメインに特異的に結合し、PDGFRβ活性を中和する第1の抗原結合領域であって、ここで、該PDGFRβ結合領域は、LCDR1 PDGFR 、LCDR2 PDGFR 及びLCDR3 PDGFR のCDRを含むV L ドメイン(V L−PDGFR )並びにHCDR1 PDGFR 、HCDR2 PDGFR 及びHCDR3 PDGFR のCDRを含むV H ドメイン(V H−PDGFR )を含み、ここで、
LCDR1 PDGFR 、LCDR2 PDGFR 及びLCDR3 PDGFR がそれぞれ配列番号46の残基24〜40、残基56〜62及び残基95〜103に示すアミノ酸配列を有し、
HCDR1 PDGFR 、HCDR2 PDGFR 及びHCDR3 PDGFR がそれぞれ配列番号48の残基31〜35、残基50〜66及び残基99〜111に示すアミノ酸配列を有する、第1の抗原結合領域;ならびに
(ii)VEGF−Aに特異的に結合し、VEGF−A活性を中和する第2の抗原結合領域であって、ここで、該VEGF−A結合領域は、LCDR1 VEGF 、LCDR2 VEGF 及びLCDR3 VEGF のCDRを含むV L ドメイン(V L−VEGF )並びにHCDR1 VEGF 、HCDR2 VEGF 及びHCDR3 VEGF のCDRを含むV H ドメイン(V H−VEGF )を含み、ここで、
LCDR1 VEGF 、LCDR2 VEGF 及びLCDR3 VEGF がそれぞれ配列番号278の残基24〜34、残基50〜56及び残基89〜97に示すアミノ酸配列を有し、
HCDR1 VEGF 、HCDR2 VEGF 及びHCDR3 VEGF がそれぞれ配列番号280の残基31〜35、残基50〜66及び残基99〜110に示すアミノ酸配列を有する、第2の抗原結合領域、
を含み、ここで、該第1の抗原結合領域および該第2の抗原結合領域は、各々10 8 M −1 以上の結合親和性(Ka)を示す、二重特異性抗体。 - 前記V L−PDGFR ドメインおよび前記V H−PDGFR ドメインがそれぞれ配列番号46および48に示されるアミノ酸配列を含む、請求項1に記載の二重特異性抗体。
- 前記V L−VEGF ドメイン及び前記V H−VEGF ドメインがそれぞれ配列番号278及び280に示されるアミノ酸配列を含む、請求項1に記載の二重特異性抗体。
- V L−PDGFR 、V H−PDGFR 、V L−VEGF 及びV H−VEGF がそれぞれ配列番号46、48、278及び280に示されるアミノ酸配列を含む、請求項1〜3のいずれか1項に記載の二重特異性抗体。
- 免疫グロブリン重鎖定常領域、例えばFcフラグメントを必要に応じて含む、請求項1〜4のいずれか1項に記載の二重特異性抗体。
- 前記Fcフラグメントが、1つ又は複数のエフェクター機能を低下又は消失させるように修飾されたFc領域を含む、請求項5に記載の二重特異性抗体。
- tascFv、biscFv又はbiAbである、請求項5に記載の二重特異性抗体。
- 二単鎖Fv(biscFv)である、請求項1から7までのいずれか一項に記載の二重特異性抗体。
- 前記biscFvが、配列番号628のアミノ酸残基20〜773を含む、請求項8に記載の二重特異性抗体。
- 請求項1から9までのいずれか一項に記載の二重特異性抗体、及び
薬学的に許容される担体
を含む医薬組成物。 - 請求項1から9までのいずれか一項に記載の二重特異性抗体をコードする単離されたポリヌクレオチド。
- 前記ポリヌクレオチドが配列番号45および47の核酸配列を含む、請求項11に記載の単離されたポリヌクレオチド。
- 前記ポリヌクレオチドが配列番号277および279の核酸配列を含む、請求項11または12に記載の単離されたポリヌクレオチド。
- 請求項11から13までのいずれか一項に記載のポリヌクレオチドを含む発現ベクター。
- 請求項14に記載の発現ベクターを含む宿主細胞。
- 請求項1から9までのいずれか一項に記載の二重特異性抗体を産生する方法であって、
請求項15に記載の宿主細胞を該二重特異性抗体が発現される条件下で培養する工程、及び
該宿主細胞から該二重特異性抗体を単離する工程
を含む、方法。 - 血管新生障害を治療するための組成物であって、請求項1から9までのいずれか一項に記載の二重特異性抗体を含む、組成物。
- 前記血管新生障害が:
(a)膵臓癌、腎細胞癌(RCC)、結腸直腸癌、非小細胞肺癌(NSCLC)、消化管間質腫瘍(GIST)及び神経膠芽腫からなる群より選択される癌のような固形腫瘍の成長によって特徴付けられる癌;または
(b)加齢性黄班変性、糖尿病性網膜症、虹彩新生血管形成、血管新生緑内障及び増殖性硝子体網膜症からなる群より選択される血管新生眼障害のような血管新生眼障害;
である、請求項17に記載の組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4006808P | 2008-03-27 | 2008-03-27 | |
US61/040,068 | 2008-03-27 | ||
US14454709P | 2009-01-14 | 2009-01-14 | |
US61/144,547 | 2009-01-14 | ||
PCT/US2009/038495 WO2009120922A2 (en) | 2008-03-27 | 2009-03-27 | Compositions and methods for inhibiting pdgfrbeta and vegf-a |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013244129A Division JP5855627B2 (ja) | 2008-03-27 | 2013-11-26 | PDGFRβおよびVEGF−Aを阻害するための組成物および方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011518546A JP2011518546A (ja) | 2011-06-30 |
JP2011518546A5 true JP2011518546A5 (ja) | 2012-11-01 |
JP5425180B2 JP5425180B2 (ja) | 2014-02-26 |
Family
ID=40793092
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011502087A Expired - Fee Related JP5425180B2 (ja) | 2008-03-27 | 2009-03-27 | PDGFRβおよびVEGF−Aを阻害するための組成物および方法 |
JP2013244129A Expired - Fee Related JP5855627B2 (ja) | 2008-03-27 | 2013-11-26 | PDGFRβおよびVEGF−Aを阻害するための組成物および方法 |
JP2015240210A Expired - Fee Related JP6140796B2 (ja) | 2008-03-27 | 2015-12-09 | PDGFRβおよびVEGF−Aを阻害するための組成物および方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013244129A Expired - Fee Related JP5855627B2 (ja) | 2008-03-27 | 2013-11-26 | PDGFRβおよびVEGF−Aを阻害するための組成物および方法 |
JP2015240210A Expired - Fee Related JP6140796B2 (ja) | 2008-03-27 | 2015-12-09 | PDGFRβおよびVEGF−Aを阻害するための組成物および方法 |
Country Status (14)
Country | Link |
---|---|
US (2) | US9441034B2 (ja) |
EP (3) | EP2604279A1 (ja) |
JP (3) | JP5425180B2 (ja) |
AU (3) | AU2009228158B2 (ja) |
CA (1) | CA2716882A1 (ja) |
CY (1) | CY1115382T1 (ja) |
DK (1) | DK2274008T3 (ja) |
ES (1) | ES2456296T3 (ja) |
HR (1) | HRP20140244T1 (ja) |
IL (3) | IL207618A (ja) |
PL (1) | PL2274008T3 (ja) |
PT (1) | PT2274008E (ja) |
SI (1) | SI2274008T1 (ja) |
WO (1) | WO2009120922A2 (ja) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
US20120134993A1 (en) * | 2009-03-27 | 2012-05-31 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
MX2013000667A (es) | 2010-07-19 | 2013-02-27 | Hoffmann La Roche | Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anticancer. |
CA2805709A1 (en) | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
EP4303236A3 (en) | 2010-11-30 | 2024-03-20 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
US9499608B2 (en) | 2011-06-08 | 2016-11-22 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration |
EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
CA2853230C (en) | 2011-10-31 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
TWI591074B (zh) * | 2011-12-05 | 2017-07-11 | X 染色體有限公司 | PDGF受體β結合多肽 |
EP3421488A3 (en) * | 2012-03-14 | 2019-04-17 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
EP2966088B1 (en) * | 2012-08-31 | 2019-10-16 | The Scripps Research Institute | Antibodies that modulate eukaryotic cells |
WO2014034735A1 (ja) * | 2012-08-31 | 2014-03-06 | 国立大学法人 大阪大学 | Vegf及び/又はアンギオポエチン-2の特異的エピトープを含むdnaワクチン |
US9777067B2 (en) | 2012-09-27 | 2017-10-03 | Massachusetts Institute Of Technology | HER2- and VEGF-A-binding proteins with enhanced stability |
JO3405B1 (ar) * | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
SG10201707501TA (en) | 2013-03-13 | 2017-10-30 | Genzyme Corp | Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof |
CN104341504B (zh) * | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | 双特异性抗体 |
EP3466445A1 (en) | 2013-11-06 | 2019-04-10 | Janssen Biotech, Inc. | Anti-ccl17 antibodies |
CN113603788A (zh) | 2014-01-15 | 2021-11-05 | 卡德门企业有限公司 | 免疫调节剂 |
US10982221B2 (en) | 2014-01-27 | 2021-04-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Plant-derived antibodies and derivatives that reduce risk of antibody-dependent enhancement (ADE) of infection |
NZ724710A (en) | 2014-04-07 | 2024-02-23 | Chugai Pharmaceutical Co Ltd | Immunoactivating antigen-binding molecule |
TW201623333A (zh) | 2014-05-13 | 2016-07-01 | Chugai Pharmaceutical Co Ltd | 對具有免疫抑制機能之細胞的t細胞重定向抗原結合分子 |
HUE047385T2 (hu) | 2014-06-06 | 2020-04-28 | Bristol Myers Squibb Co | Antitestek glükokortikoid indukált tumornekrózis faktor receptor (GITR) ellen és annak felhasználásai |
EP3161002A1 (en) * | 2014-06-27 | 2017-05-03 | Innate Pharma | MULTISPECIFIC NKp46 BINDING PROTEINS |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
WO2015200905A2 (en) * | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
WO2016061562A2 (en) | 2014-10-17 | 2016-04-21 | Kodiak Sciences Inc. | Butyrylcholinesterase zwitterionic polymer conjugates |
AR102417A1 (es) * | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
JP2018517660A (ja) | 2015-03-20 | 2018-07-05 | ヨハン ウォルフガング ゲーテ−ウニベルジテート フランクフルト アム マイン | 周皮細胞長鎖非コーディングrna |
WO2016196792A1 (en) | 2015-06-03 | 2016-12-08 | Bristol-Myers Squibb Company | Anti-gitr antibodies for cancer diagnostics |
EP3319994B1 (en) | 2015-07-06 | 2024-02-07 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
EP3334762A1 (en) | 2015-08-14 | 2018-06-20 | Allergan, Inc. | Heavy chain only antibodies to pdgf |
TWI799366B (zh) * | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
AU2016332725A1 (en) | 2015-09-29 | 2018-03-22 | Celgene Corporation | PD-1 binding proteins and methods of use thereof |
EP3368066A1 (en) * | 2015-10-30 | 2018-09-05 | Eli Lilly and Company | Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof |
JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法 |
US11649293B2 (en) | 2015-11-18 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
WO2017087678A2 (en) | 2015-11-19 | 2017-05-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
WO2017106609A2 (en) * | 2015-12-16 | 2017-06-22 | Kadmon Corporation, Llc. | Pdgfr beta antibody |
EP4059492B1 (en) | 2015-12-16 | 2024-04-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods of manufacturing protein microparticles |
KR20180091918A (ko) | 2015-12-28 | 2018-08-16 | 추가이 세이야쿠 가부시키가이샤 | Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법 |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
MX2018010988A (es) | 2016-03-14 | 2019-01-21 | Chugai Pharmaceutical Co Ltd | Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer. |
WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
RU2656160C2 (ru) * | 2016-08-17 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека |
US10919958B2 (en) | 2016-08-23 | 2021-02-16 | Medimmune Limited | Anti-VEGF-A antibodies and uses thereof |
EP3515943A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS |
US10751414B2 (en) | 2016-09-19 | 2020-08-25 | Celgene Corporation | Methods of treating psoriasis using PD-1 binding antibodies |
EP3559028A1 (en) * | 2016-12-23 | 2019-10-30 | Visterra, Inc. | Binding polypeptides and methods of making the same |
KR101908330B1 (ko) * | 2017-02-17 | 2018-10-16 | 인제대학교 산학협력단 | 신규 항-vegf 항체 및 이를 유효성분으로 포함하는 나이관련 황반변성 예방 또는 치료용 조성물 |
US20180289802A1 (en) * | 2017-03-29 | 2018-10-11 | Celgene Corporation | Formulations comprising pd-1 binding proteins and methods of making thereof |
JP6911490B2 (ja) * | 2017-04-26 | 2021-07-28 | 東ソー株式会社 | 安定型Fc結合性タンパク質、当該タンパク質の製造方法および当該タンパク質を用いた抗体吸着剤 |
JP7274426B2 (ja) | 2017-05-16 | 2023-05-16 | ブリストル-マイヤーズ スクイブ カンパニー | 抗gitrアゴニスト抗体での癌の処置 |
CN109022415B (zh) * | 2017-06-12 | 2023-09-15 | 上海睿智化学研究有限公司 | PDGFRβ单克隆重链抗体杂交瘤细胞及其制备方法和应用 |
SG11202001551YA (en) | 2017-08-21 | 2020-03-30 | Adagene Inc | Dynamic human heavy chain antibody libraries |
KR20200054209A (ko) * | 2017-08-21 | 2020-05-19 | 아다진 인크. | 동적 인간 항체 경쇄 라이브러리 |
CN108094772A (zh) * | 2017-12-08 | 2018-06-01 | 桂林莱茵生物科技股份有限公司 | 一种罗汉果果汁及其制备方法 |
AU2019227997A1 (en) * | 2018-03-02 | 2020-09-24 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
AU2019328575A1 (en) | 2018-08-30 | 2021-02-25 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
SG11202101779RA (en) | 2018-08-30 | 2021-03-30 | Hcw Biologics Inc | Multi-chain chimeric polypeptides and uses thereof |
KR20210069639A (ko) | 2018-08-30 | 2021-06-11 | 에이치씨더블유 바이올로직스, 인크. | 단일-사슬 키메라 폴리펩타이드 및 이의 용도 |
WO2020071881A1 (ko) * | 2018-10-05 | 2020-04-09 | 서울대학교산학협력단 | Pdgf 수용체에 대한 항체 및 이의 용도 |
AU2019370339A1 (en) * | 2018-11-01 | 2021-06-10 | Shandong New Time Pharmaceutical Co., Ltd. | Bispecific antibody and use thereof |
JP2022537054A (ja) | 2019-06-21 | 2022-08-23 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 多鎖キメラポリペプチドおよびその使用 |
CN112168971B (zh) * | 2019-07-03 | 2023-04-04 | 义慧科技(深圳)有限公司 | 抗vegf抗体和pdgf/pdgfr抑制剂在制备治疗表达fgf2肿瘤的药物的应用 |
WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
CA3170712A1 (en) * | 2020-02-07 | 2021-08-12 | Biorion Technologies B.V. | Platelet derived growth factor receptor (pdgfr) antibodies, conjugates, compositions, and uses thereof. |
EP4103599A1 (en) | 2020-02-11 | 2022-12-21 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
EP4103601A2 (en) | 2020-02-11 | 2022-12-21 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
CN115362169A (zh) | 2020-02-11 | 2022-11-18 | Hcw生物科技公司 | 色谱树脂以及其用途 |
AU2021262794A1 (en) | 2020-04-29 | 2022-11-24 | HCW Biologics, Inc. | Anti-CD26 proteins and uses thereof |
JP2023527869A (ja) | 2020-06-01 | 2023-06-30 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 加齢関連障害の治療法 |
WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス,インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
BR112023024724A2 (pt) * | 2021-05-28 | 2024-02-15 | Dana Farber Cancer Inst Inc | Construtos de anticorpos multiespecíficos contra o muc1-c/domínio extracelular (muc1-c/ecd) |
TW202330604A (zh) * | 2021-09-29 | 2023-08-01 | 美商蜻蜓醫療公司 | 靶向baff—r的抗體及其用途 |
WO2023164510A1 (en) * | 2022-02-23 | 2023-08-31 | Xencor, Inc. | Anti-cd28 x anti-psma antibodies |
WO2023168363A1 (en) | 2022-03-02 | 2023-09-07 | HCW Biologics, Inc. | Method of treating pancreatic cancer |
WO2024044732A2 (en) * | 2022-08-25 | 2024-02-29 | Bright Biopharmaceutical | Multispecific antibodies and uses thereof |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE54046B1 (en) | 1981-08-25 | 1989-05-24 | Celltech Ltd | Expression vectors |
US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US4486533A (en) | 1982-09-02 | 1984-12-04 | St. Louis University | Filamentous fungi functional replicating extrachromosomal element |
US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
US4977092A (en) | 1985-06-26 | 1990-12-11 | Amgen | Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
US4661454A (en) | 1983-02-28 | 1987-04-28 | Collaborative Research, Inc. | GAL1 yeast promoter linked to non galactokinase gene |
US5139936A (en) | 1983-02-28 | 1992-08-18 | Collaborative Research, Inc. | Use of the GAL1 yeast promoter |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
DE3578435D1 (de) | 1984-12-06 | 1990-08-02 | Labofina Sa | Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden. |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5063154A (en) | 1987-06-24 | 1991-11-05 | Whitehead Institute For Biomedical Research | Pheromone - inducible yeast promoter |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5268358A (en) | 1988-12-08 | 1993-12-07 | Cor Therapeutics, Inc. | PDGF receptor blocking peptides |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5162228A (en) | 1988-12-28 | 1992-11-10 | Takeda Chemical Industries, Ltd. | Gylceraldehyde-3-phosphate dehydrogenase gene and promoter |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5162222A (en) | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
JP3202999B2 (ja) | 1991-01-31 | 2001-08-27 | 協和醗酵工業株式会社 | 肝移行性リポソーム製剤 |
EP0584082B1 (en) | 1991-01-31 | 2000-05-31 | Cor Therapeutics, Inc. | Domains of extracellular region of human platelet derived growth factor receptor polypeptides |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
US5298418A (en) | 1991-09-16 | 1994-03-29 | Boyce Thompson Institute For Plant Research, Inc. | Cell line isolated from larval midgut tissue of Trichoplusia ni |
WO1993008210A1 (en) | 1991-10-18 | 1993-04-29 | Beth Israel Hospital Association | Vascular permeability factor targeted compounds |
ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
US20020009443A1 (en) | 1991-12-02 | 2002-01-24 | Vanitha Ramakrishman | Inhibitory immunoglobulin polypeptides to human pdgf beta receptor |
US5817310A (en) | 1991-12-02 | 1998-10-06 | Cor Therapeutics, Inc. | Inhibitory immunoglobulin polypeptides to human PDGF beta receptor |
CA2144651A1 (en) | 1992-09-14 | 1994-03-31 | Timothy J. Miller | Immortalized cells and uses therefor |
DE69233803D1 (de) | 1992-10-28 | 2011-03-31 | Genentech Inc | Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten |
WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
US5641655A (en) | 1994-11-30 | 1997-06-24 | Zymogenetics, Inc. | Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide |
US5654173A (en) | 1996-08-23 | 1997-08-05 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
US5716808A (en) | 1995-11-09 | 1998-02-10 | Zymogenetics, Inc. | Genetic engineering of pichia methanolica |
US5955349A (en) | 1996-08-26 | 1999-09-21 | Zymogenetics, Inc. | Compositions and methods for producing heterologous polypeptides in Pichia methanolica |
US5882644A (en) | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
US5736383A (en) | 1996-08-26 | 1998-04-07 | Zymogenetics, Inc. | Preparation of Pichia methanolica auxotrophic mutants |
CN1230997A (zh) | 1996-07-17 | 1999-10-06 | 津莫吉尼蒂克斯公司 | 甲醇毕赤酵母的转化 |
AU743758B2 (en) * | 1997-04-07 | 2002-02-07 | Genentech Inc. | Anti-VEGF antibodies |
US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
MXPA01012385A (es) * | 1999-06-03 | 2002-09-02 | Human Genome Sciences Inc | Proteinas angiogenicas y usos de las mismas. |
CA2409991A1 (en) | 2000-05-24 | 2001-11-29 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
AU3942202A (en) | 2000-11-30 | 2002-06-11 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
IL158419A0 (en) | 2001-04-19 | 2004-05-12 | Scripps Research Inst | Methods and composition for the production of orthoganal trna-aminoacyl trna synthetase pairs |
MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
AU2003209446B2 (en) | 2002-03-01 | 2008-09-25 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
KR101228124B1 (ko) | 2002-06-14 | 2013-01-31 | 이뮤노메딕스, 인코오포레이티드 | 단클론 항체 pam4 및 췌장암의 진단 및 치료를 위한이들의 용도 |
EP1513929A4 (en) | 2002-06-18 | 2006-04-19 | Zymogenetics Inc | HYBRID VECTOR WITH A CYTOMEGALOVIRUS ENHANCER AND PROMOTER OF MYELOPROLIFERATIVE SARCOMA VIRUS |
EP2267032A3 (en) | 2002-11-08 | 2011-11-09 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
WO2005014618A2 (en) | 2003-08-08 | 2005-02-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
JP4951339B2 (ja) | 2003-08-27 | 2012-06-13 | オプソテツク・コーポレイシヨン | 眼血管新生疾患の治療のための併用療法 |
US20080085902A1 (en) | 2003-09-23 | 2008-04-10 | Guido Bold | Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent |
US20050282233A1 (en) * | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
EP1786918A4 (en) | 2004-07-17 | 2009-02-11 | Imclone Systems Inc | NEW BISPECIFIC ANTIBODY TETRAVALENT |
US20060234347A1 (en) * | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
AU2006327175A1 (en) | 2005-12-21 | 2007-06-28 | Medimmune, Llc | Epha2 bite molecules and uses thereof |
WO2007140534A1 (en) * | 2006-06-08 | 2007-12-13 | Csl Limited | Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling |
WO2007147019A2 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
US20110118185A9 (en) | 2007-02-21 | 2011-05-19 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
CN101707882A (zh) | 2007-04-17 | 2010-05-12 | 伊姆克罗尼责任有限公司 | PDGFRβ特异性抑制剂 |
JP2011500086A (ja) | 2007-10-22 | 2011-01-06 | シェーリング コーポレイション | 完全ヒト抗vegf抗体および使用方法 |
-
2009
- 2009-03-27 WO PCT/US2009/038495 patent/WO2009120922A2/en active Application Filing
- 2009-03-27 EP EP13159549.8A patent/EP2604279A1/en not_active Withdrawn
- 2009-03-27 US US12/934,756 patent/US9441034B2/en active Active
- 2009-03-27 AU AU2009228158A patent/AU2009228158B2/en not_active Ceased
- 2009-03-27 PL PL09724060T patent/PL2274008T3/pl unknown
- 2009-03-27 SI SI200930882T patent/SI2274008T1/sl unknown
- 2009-03-27 ES ES09724060.0T patent/ES2456296T3/es active Active
- 2009-03-27 DK DK09724060.0T patent/DK2274008T3/da active
- 2009-03-27 EP EP13159556.3A patent/EP2604280A3/en not_active Withdrawn
- 2009-03-27 PT PT97240600T patent/PT2274008E/pt unknown
- 2009-03-27 JP JP2011502087A patent/JP5425180B2/ja not_active Expired - Fee Related
- 2009-03-27 CA CA2716882A patent/CA2716882A1/en not_active Abandoned
- 2009-03-27 EP EP09724060.0A patent/EP2274008B1/en active Active
-
2010
- 2010-08-15 IL IL207618A patent/IL207618A/en active IP Right Grant
-
2013
- 2013-11-26 JP JP2013244129A patent/JP5855627B2/ja not_active Expired - Fee Related
-
2014
- 2014-03-17 HR HRP20140244AT patent/HRP20140244T1/hr unknown
- 2014-05-23 CY CY20141100361T patent/CY1115382T1/el unknown
- 2014-05-27 AU AU2014202867A patent/AU2014202867B2/en not_active Ceased
- 2014-11-11 IL IL235618A patent/IL235618A/en active IP Right Grant
- 2014-11-11 IL IL235619A patent/IL235619A/en not_active IP Right Cessation
-
2015
- 2015-12-09 JP JP2015240210A patent/JP6140796B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-11 US US15/207,428 patent/US9708390B2/en active Active
- 2016-12-14 AU AU2016273894A patent/AU2016273894A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011518546A5 (ja) | ||
JP2017514461A5 (ja) | ||
JP2020531048A5 (ja) | ||
HRP20140244T1 (hr) | Sastavi i metode za inhibiranje pdgfrbeta i vegf-a | |
JP2017535257A5 (ja) | ||
JP2019533989A5 (ja) | 抗pd−1抗体及びその使用 | |
JP2018503380A5 (ja) | ||
JP2015503909A5 (ja) | ||
JP2011046732A5 (ja) | ||
JP2017052784A5 (ja) | ||
JP2018534933A5 (ja) | ||
JP2018506961A5 (ja) | ||
JP2015533853A5 (ja) | ||
JP2014526898A5 (ja) | ||
JP2013538553A5 (ja) | ||
JP2018536632A5 (ja) | B7‐h3に特異的に結合する分子及びpd‐1に特異的に結合する分子 | |
JP2016536020A5 (ja) | ||
JP2018521691A5 (ja) | ||
JP2015514110A5 (ja) | ||
JP2013198490A5 (ja) | ||
JP2015535828A5 (ja) | ||
JP2010507594A5 (ja) | ||
JP2010526028A5 (ja) | ||
JP2009297037A5 (ja) | ||
JP2013538057A5 (ja) |